MRC Impact Acceleration Award: Single-Step Support for Medical Product Development

MRC Impact Acceleration Award: Single-Step Support for Medical Product Development

The MRC Impact Acceleration Award is an open Medical Research Council (MRC) grant for academically led translational work on a new or repurposed medicine, medical device, diagnostic, or other medical product. The award supports one high-risk development step: a tightly defined piece of work that generates the critical data needed to decide whether a product should progress, change direction, or stop.

This opportunity was formerly called the Gap Fund: single-step support for medical product development. The old Gap Fund page is closed, and UKRI now directs applicants to the MRC Impact Acceleration Award page. The name changed, but the central proposition remains a focused bridge between early translational work and more substantial product-development funding. Read the current award page before preparing an application, because the current form, programme names, and resubmission rules are the ones that apply.

At a glance

The deadline field for this listing is the single date 2026-11-11. UKRI states that it must receive the application by 4:00pm UK time on that date; an application cannot be submitted after the deadline. Your research organisation may set an earlier internal deadline for checks, costing, approvals, or submission.

What changed from the Gap Fund

The former Gap Fund opportunity is not a separate open call. UKRI’s closed Gap Fund page says it has been replaced by the UKRI Translation: MRC Impact Acceleration Awards opportunity. The replacement page explicitly identifies the current award as formerly known as the Gap Fund, so applicants should not treat this as a wholly unrelated scheme or continue using the closed page as their submission route.

The current page places the award before the MRC Proof of Concept funding opportunity, which it identifies as the successor name for the larger route formerly known as the Developmental Pathway Funding Scheme (DPFS). The practical sequence is therefore:

1. Early concept and pump-priming work, potentially including an MRC Impact Acceleration Account.
2. One high-risk development step through the Impact Acceleration Award.
3. A larger MRC Proof of Concept application or another appropriate onward route if the evidence supports progression.

That sequence does not mean every project must apply to all three stages. It means the proposed step must have a credible relationship to the work already done and to the decision that follows. A proposal can also be useful when the result is negative, provided the study is designed to show clearly why the proposed intervention should not proceed or what needs to change.

What the award is designed to support

The award is for academically led translational projects that have moved beyond a new idea and have generated some supporting data. The application must identify one critical gap in development and show how the proposed work will address it. The goal is not to fund a complete product programme or a collection of loosely related experiments.

Eligible subject areas cover all human diseases and medical interventions, including UK healthcare and global health contexts. Examples of supported development work include:

• high-risk elements of therapeutic discovery, quantification, or validation
• early prototype development and prototype testing
• initial biomarker validation, but not biomarker identification
• vector identification or optimisation
• hit expansion medicinal chemistry
• new small-molecule medicines
• vaccines for infectious or non-infectious disease
• biologics such as antibodies, peptides, and proteins
• advanced therapeutics such as gene, cell, RNA, nucleic-acid, and T-cell therapies
• complex medicines including PROTACs, molecular glues, and antibody-drug conjugates
• regenerative medicine approaches
• repurposing clinical studies or existing therapies for new indications
• medical devices and medical imaging technology
• digital healthcare and app development
• behavioural and psychological interventions
• radiotherapy and radiation protocols

The award can include artificial intelligence when it is a core enabling technology rather than a minor feature. If the project involves significant AI, the application has a compulsory AI section. The applicant must select the relevant category, explain why the available data or planned data collection is sufficient, describe the method and expertise, and set measurable success criteria for de-risking the work.

The single-step requirement

The strongest fit is a project with one important decision at its centre. State the step in a sentence that a non-specialist can understand: for example, whether a prototype meets a pre-defined performance threshold in the intended setting, whether a delivery vector can be optimised to a usable level, or whether an assay can validate a biomarker sufficiently for the next development stage.

The application should connect four things:

• the existing evidence that makes the proposed step worth testing
• the specific technical or translational uncertainty that remains
• the method and success criteria that will resolve that uncertainty
• the funding or patient-benefit decision that follows the result

Do not turn the step into several work packages. The current guidance says the award focuses on one goal rather than multiple steps, and applications with multiple work packages are not supportable. A larger budget does not justify adding unrelated aims. Request the amount needed for the defined goal; request the maximum only when the scientific need supports it.

Eligibility and limits to check early

The project lead must be based at an MRC-eligible research organisation, must direct the project, and must be actively engaged in the work. Where the lead or another applicant does not have an employment contract covering the proposed project, the research organisation must confirm that contracts will be extended if the application succeeds and that the necessary support, including mentorship and career development for early career researchers, will be provided.

An international research organisation cannot be the lead organisation, subject to the specific MRC Unit The Gambia and MRC/UVRI and LSHTM Uganda Research Unit exceptions stated by UKRI. International researchers may participate as project co-leads (international) where the rules permit and their intellectual contribution and added value are explained. Other international collaborators, and UK partners outside approved organisations, should generally be included as project partners.

There is demand management in the current cycle: an individual can submit only one application as project lead. The current page also says that uninvited resubmissions submitted after 1 April 2026 to MRC, UKRI, or another funder will not be accepted. If a previous application might count as a resubmission, contact MRC before submitting rather than assuming that a minimally changed version is acceptable.

The programme does not support fundamental or investigative work without a product development plan, disease-mechanism clinical studies, preliminary concept-data generation that belongs with an Impact Acceleration Account, pre-clinical safety and toxicology work, or early- and late-phase clinical trials that belong with other routes. It also excludes late-phase global health trials, NHS service-delivery interventions, multiple-work-package applications, and the same or similar applications rejected by another MRC panel in the last 12 months.

Funding and eligible costs

The full economic cost of a project must be between £50,000 and £300,000. MRC provides 80% of FEC and 100% of permitted exceptions. Exceeding the permitted funding limit can cause rejection at the initial checks stage, so the host research office should review the costing before submission.

Potentially eligible costs include:

• a contribution to the salary of the project lead and co-leads
• research and technical staff
• research consumables
• equipment
• eligible travel, excluding conference attendance
• data preservation, data sharing, and dissemination
• estates and indirect costs
• public partnerships and related activities, including payments to public contributors
• eligible work undertaken at international organisations by international project co-leads

International costs for applicants from high-income countries, India, and China must not exceed 30% of the total resources requested. There is no cap on costs requested for international applicants from countries on the OECD DAC list, subject to the other eligibility and costing rules.

MRC will not fund PhD studentships, publication costs, conference costs, patent filing or other costs for applying for IP protection, or money used as a bridge between grants. A budget should show how each requested item contributes to the single development step and how the work will be completed within six to 18 months.

How to apply in the current cycle

Applications use the new UKRI Funding Service, not the former Je-S system. The lead research organisation is the only organisation that can submit the application. If the lead is an NHS organisation, check early that it is available in the Funding Service because organisation setup can require additional work.

Use this sequence:

1. Open the current UKRI opportunity page and select Start application.
2. Confirm that you are the project lead.
3. Sign in or create a Funding Service account, selecting and verifying the lead organisation.
4. Answer the application questions in the Funding Service. You can save work and return to it, or prepare text offline and copy it into the form.
5. Review the application in read-only view before sending it to the research office.
6. Send the completed application to the research office for checking.
7. Resolve any costing, eligibility, hosting, or institutional-support issues returned by the research office.
8. Ask the research office to submit the checked application to UKRI before 4:00pm UK time on 11 November 2026.

The form is not a place to rely on external links to fill gaps in the explanation. UKRI says applications should be self-contained and that hyperlinks should be used only for direct reference information. If images are used, they must carry a descriptive caption, be inserted on their own line, and convey important visual information rather than add paragraphs of text or tables.

Materials and form sections to prepare

The current form asks for more than a project abstract. Prepare a concise evidence trail that covers:

• Background to application: the scientific background, previous funding and funders, any resubmission status, and relevant correspondence with MRC.
• Fit to the opportunity: an elevator pitch, the single high-risk development step, the connection to substantive funding or direct patient benefit, and the likely impact and success criteria. All four compulsory questions need an answer.
• MRC Impact Acceleration Account context: confirm with the research office whether the host organisation holds or has held an MRC IAA. If it does, explain why this proposal is more suitable for the Impact Acceleration Award. If it does not, explain that the host does not provide that earlier-stage route.
• Approach: describe the work, controls, measurements, decision thresholds, data management, and the interpretation of positive, mixed, and negative results.
• Team capability: name the people who will deliver the work and make the roles consistent with the proposed methods.
• Research organisation support: obtain approval from an appropriate institutional authority, such as a technology-transfer or translational research office, for the named support and research environment.
• Project partners: identify only partners with an integral role. Every identified project partner needs a support letter or email that explains its contribution. General letters from people who are not project partners are not useful for assessment.
• Resources and costs: tie personnel, equipment, consumables, access, and partner contributions to the one-step plan.
• Intellectual property rights: explain background IP, expected project IP, ownership, access, and the strategy for downstream development, clinical uptake, or commercialisation.
• Ethics, responsible research and innovation, and trusted research: address relevant human, animal, data, international-collaboration, security, and governance issues.

For a project with significant AI use, complete the dedicated AI questions rather than treating the algorithm as a detail inside the approach. For an industry or company partner, check whether the Industry Collaboration Framework applies and answer the required collaboration and IP questions for each relevant partner.

How applications are assessed

Applications are assessed by members of the MRC Proof of Concept panel, with additional expertise sourced when needed. UKRI says it will not obtain external expert review comments as part of this process. The assessment areas are background, approach including data management, team capability, IP rights, resources and costs, and ethics and responsible research and innovation.

The panel also considers the significance of the clinical or medical need, the scientific rationale, deliverability, the realism of the future development plan, and the IP strategy. High-risk work is welcome, but the plan must make it possible to reach a clear decision about onward translation at the end of the award. A negative result is acceptable when it is informative and tied to a pre-defined decision rule; a vague failure scenario is not a substitute for a study design.

UKRI says the assessment aim is to complete within 12 weeks of the closing date, with outcomes communicated within 10 working days of the panel meeting and feedback within eight to 10 weeks of that meeting. These are stated service aims, not a promise of a particular decision date. Panel decisions are not open to appeal.

Practical readiness checklist

Before asking the research office to review the application, confirm that:

• the project lead and lead organisation satisfy MRC eligibility
• the proposal contains one development step, not a disguised multi-project programme
• the starting evidence is clear and supports the proposed test
• every success threshold is measurable
• the result will support a defined next action, including a stop or pivot if appropriate
• the duration and budget match the work rather than the maximum award
• any IAA relationship is accurately described
• project partners are listed consistently and have supplied the right support statements
• international roles and costs follow UKRI rules
• AI, IP, ethics, data management, and trusted-research questions are answered where relevant
• the research office has enough time to check and submit the final version

Official contacts

For opportunity-specific questions, UKRI lists [email protected]. For general MRC funding questions, it lists [email protected]. Questions about the Funding Service should go to [email protected] or 01793 547490. UKRI asks applicants to include the council and opportunity name in the email subject and the application reference number where available.

Bottom line

The MRC Impact Acceleration Award is the current open name for the former Gap Fund. It is a focused grant of £50,000 to £300,000 FEC for one high-risk medical product development step, not a general product-development budget. A credible application starts with existing evidence, isolates one uncertainty, defines the data that will resolve it, and shows what the team will do with either result.

Use the replacement UKRI page and Funding Service route for the current cycle. Make sure the lead organisation and research office are involved early, and treat 11 November 2026 at 4:00pm UK time as the external cut-off rather than the time to begin final checks.

Official links

• Current funding opportunity: https://www.ukri.org/opportunity/ukri-translation-mrc-impact-acceleration-awards/
• Closed former Gap Fund page and replacement notice: https://www.ukri.org/opportunity/gap-fund-single-step-support-for-medical-product-development/